Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 453

1.

The nephrology crystal ball: the medium-term future.

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Massy Z, Rychlık I, Soler MJ, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Oct 9. pii: gfz199. doi: 10.1093/ndt/gfz199. [Epub ahead of print]

PMID:
31598700
2.

The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary.

Kramer A, Pippias M, Noordzij M, Stel VS, Andrusev AM, Aparicio-Madre MI, Arribas Monzón FE, Åsberg A, Barbullushi M, Beltrán P, Bonthuis M, Caskey FJ, Castro de la Nuez P, Cernevskis H, De Meester J, Finne P, Golan E, Heaf JG, Hemmelder MH, Ioannou K, Kantaria N, Komissarov K, Korejwo G, Kramar R, Lassalle M, Lopot F, Macário F, Mackinnon B, Pálsson R, Pechter Ü, Piñera VC, Santiuste de Pablos C, Segarra-Medrano A, Seyahi N, Slon Roblero MF, Stojceva-Taneva O, Vazelov E, Winzeler R, Ziginskiene E, Massy Z, Jager KJ.

Clin Kidney J. 2019 Feb 26;12(5):702-720. doi: 10.1093/ckj/sfz011. eCollection 2019 Oct.

3.

Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Frémeaux-Bacchi V.

J Am Soc Nephrol. 2019 Oct 1. pii: ASN.2019040331. doi: 10.1681/ASN.2019040331. [Epub ahead of print]

PMID:
31575699
4.

New Insights into the Roles of Monocytes/Macrophages in Cardiovascular Calcification Associated with Chronic Kidney Disease.

Hénaut L, Candellier A, Boudot C, Grissi M, Mentaverri R, Choukroun G, Brazier M, Kamel S, Massy ZA.

Toxins (Basel). 2019 Sep 12;11(9). pii: E529. doi: 10.3390/toxins11090529. Review.

5.

International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.

Liabeuf S, McCullough K, Young EW, Pisoni R, Zee J, Reichel H, Pecoits-Filho R, Port FK, Stengel B, Csomor PA, Metzger M, Robinson B, Massy ZA.

Bone. 2019 Sep 4;129:115058. doi: 10.1016/j.bone.2019.115058. [Epub ahead of print]

PMID:
31493530
6.

Strategies for Phosphate Control in Patients With CKD.

Barreto FC, Barreto DV, Massy ZA, Drüeke TB.

Kidney Int Rep. 2019 Jun 20;4(8):1043-1056. doi: 10.1016/j.ekir.2019.06.002. eCollection 2019 Aug. Review.

7.

Erratum to: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Aug 9. pii: gfz137. doi: 10.1093/ndt/gfz137. [Epub ahead of print] No abstract available.

PMID:
31397476
8.

Acute kidney injury associated with lymphangitic carcinomatosis.

Sannier A, Dupuis E, Berger AK, Bischofs C, Massy ZA, Seidowsky A.

Clin Kidney J. 2018 Oct 10;12(4):527-529. doi: 10.1093/ckj/sfy099. eCollection 2019 Aug.

9.

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe.

Massy ZA, Caskey FJ, Finne P, Harambat J, Jager KJ, Nagler E, Stengel B, Sever MS, Vanholder R, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Soler MJ, Rychlík I, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Sep 1;34(9):1616. doi: 10.1093/ndt/gfz154. No abstract available.

10.

Inhibition of miR-223 expression using a sponge strategy decreases restenosis in rat injured carotids.

M'baya-Moutoula E, Marchand A, Six I, Bahrar N, Celic T, Mougenot N, Maitrias P, Massy ZA, Lompre AM, Metzinger L, Metzinger-Le Meuth V.

Curr Vasc Pharmacol. 2019 Jul 5. doi: 10.2174/1570161117666190705141152. [Epub ahead of print]

PMID:
31284864
11.

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe.

Massy ZA, Caskey FJ, Finne P, Harambat J, Jager KJ, Nagler E, Stengel B, Sever MS, Vanholder R, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Soler MJ, Rychlík I, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Sep 1;34(9):1469-1480. doi: 10.1093/ndt/gfz089. Erratum in: Nephrol Dial Transplant. 2019 Sep 1;34(9):1616.

12.

Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.

Pecoits-Filho R, Fliser D, Tu C, Zee J, Bieber B, Wong MMY, Port F, Combe C, Lopes AA, Reichel H, Narita I, Stengel B, Robinson BM, Massy Z; CKDopps Investigators.

J Clin Hypertens (Greenwich). 2019 Jul;21(7):991-1001. doi: 10.1111/jch.13563. Epub 2019 Jun 6.

13.

Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy.

Aubert CE, Liabeuf S, Amouyal C, Kemel S, Lajat-Kiss F, Lacorte JM, Halbron M, Carlier A, Salem JE, Funck-Brentano C, Perisic Matic L, Witasp A, Stenvinkel P, Phan F, Massy ZA, Hartemann A, Bourron O.

Diabetol Metab Syndr. 2019 Apr 29;11:32. doi: 10.1186/s13098-019-0429-7. eCollection 2019.

14.

Erratum.

Drüeke TB, Massy ZA.

Nephrol Dial Transplant. 2019 May 18. pii: gfz112. doi: 10.1093/ndt/gfz112. [Epub ahead of print] No abstract available.

PMID:
31102523
15.

The epidemiology of renal replacement therapy in two different parts of the world: the Latin American Dialysis and Transplant Registry versus the European Renal Association-European Dialysis and Transplant Association Registry.

Luxardo R, Kramer A, González-Bedat MC, Massy ZA, Jager KJ, Rosa-Diez G, Noordzij M; collaborators.

Rev Panam Salud Publica. 2018 Sep 7;42:e87. doi: 10.26633/RPSP.2018.87. eCollection 2018.

16.

Endothelial Microparticles in Uremia: Biomarkers and Potential Therapeutic Targets.

Favretto G, Cunha RSD, Dalboni MA, Oliveira RB, Barreto FC, Massy ZA, Stinghen AEM.

Toxins (Basel). 2019 May 13;11(5). pii: E267. doi: 10.3390/toxins11050267. Review.

17.

Mild cognitive impairment and kidney disease: clinical aspects.

Viggiano D, Wagner CA, Blankestijn PJ, Bruchfeld A, Fliser D, Fouque D, Frische S, Gesualdo L, Gutiérrez E, Goumenos D, Hoorn EJ, Eckardt KU, Knauß S, König M, Malyszko J, Massy Z, Nitsch D, Pesce F, Rychlík I, Soler MJ, Spasovski G, Stevens KI, Trepiccione F, Wanner C, Wiecek A, Zoccali C, Unwin R, Capasso G.

Nephrol Dial Transplant. 2019 Apr 9. pii: gfz051. doi: 10.1093/ndt/gfz051. [Epub ahead of print] No abstract available.

PMID:
31071220
18.

Vascular calcification - any place left for nicotinamide?

Drüeke TB, Massy ZA.

Nephrol Dial Transplant. 2019 Apr 9. pii: gfz057. doi: 10.1093/ndt/gfz057. [Epub ahead of print] No abstract available.

PMID:
31071218
19.

Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?

Lenglet A, Fabresse N, Taupin M, Gomila C, Liabeuf S, Kamel S, Alvarez JC, Drueke TB, Massy ZA.

Drugs. 2019 Jun;79(8):855-862. doi: 10.1007/s40265-019-01118-9.

PMID:
31062264
20.

Cellular and molecular mechanisms associated with ischemic stroke severity in female mice with chronic kidney disease.

Hénaut L, Grissi M, Brazier F, Assem M, Poirot-Leclercq S, Lenglet G, Boudot C, Avondo C, Boullier A, Choukroun G, Massy ZA, Kamel S, Chillon JM.

Sci Rep. 2019 Apr 23;9(1):6432. doi: 10.1038/s41598-019-42933-0.

21.

Erythropoiesis-Stimulating Agents and Mortality.

Drüeke TB, Massy ZA.

J Am Soc Nephrol. 2019 Jun;30(6):907-908. doi: 10.1681/ASN.2019030266. Epub 2019 Apr 23. No abstract available.

PMID:
31015256
22.

Reply to "Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!" by Stamp et al.

Laville SM, Stengel B, Massy ZA, Liabeuf S.

Br J Clin Pharmacol. 2019 Jun;85(6):1380-1381. doi: 10.1111/bcp.13924. Epub 2019 Apr 13. No abstract available.

PMID:
30980562
23.

Erratum to Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Massy Z, Rychlık I, Soler MJ, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Apr 12. pii: gfz070. doi: 10.1093/ndt/gfz070. [Epub ahead of print] No abstract available.

PMID:
30977814
24.

Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease.

Ureña-Torres PA, Vervloet M, Mazzaferro S, Oury F, Brandenburg V, Bover J, Cavalier E, Cohen-Solal M, Covic A, Drüeke TB, Hindié E, Evenepoel P, Frazão J, Goldsmith D, Kazama JJ, Cozzolino M, Massy ZA; ERA-EDTA CKD-MBD Working Group.

Clin Kidney J. 2018 Jul 20;12(2):269-280. doi: 10.1093/ckj/sfy061. eCollection 2019 Apr.

25.

[Middle-molecule uremic toxins: A renewed interest].

Nlandu Y, Padden M, Seidowsky A, Hamaz S, Vilaine É, Cheddani L, Essig M, Massy ZA.

Nephrol Ther. 2019 Apr;15(2):82-90. doi: 10.1016/j.nephro.2018.09.003. French.

PMID:
30954165
26.

Guideline attainment and morbidity/mortality rates in a large cohort of European haemodialysis patients (EURODOPPS).

Liabeuf S, Sajjad A, Kramer A, Bieber B, McCullough K, Pisoni R, Caskey F, Combe C, Robinson BM, Jager KJ, Massy ZA.

Nephrol Dial Transplant. 2019 Apr 1. pii: gfz049. doi: 10.1093/ndt/gfz049. [Epub ahead of print]

PMID:
30938439
27.

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients.

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, Vanholder R, Brigant B, Pletinck A, Diouf M, Burtey S, Choukroun G, Massy ZA, Metzinger L; European Uremic Toxin Work Group-EUTox.

Sci Rep. 2019 Mar 14;9(1):4477. doi: 10.1038/s41598-019-41101-8.

28.

The association between longer haemodialysis treatment times and hospitalization and mortality after the two-day break in individuals receiving three times a week haemodialysis.

Fotheringham J, Sajjad A, Stel VS, McCullough K, Karaboyas A, Wilkie M, Bieber B, Robinson BM, Massy ZA, Jager KJ.

Nephrol Dial Transplant. 2019 Sep 1;34(9):1577-1584. doi: 10.1093/ndt/gfz007.

29.

Erratum.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 28. pii: gfz047. doi: 10.1093/ndt/gfz047. [Epub ahead of print] No abstract available.

PMID:
30820538
30.

Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials.

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Massy Z, Rychlık I, Jose Soler M, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1112-1114. doi: 10.1093/ndt/gfz023.

PMID:
30815678
31.

Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a potential modulator of sodium phosphate co-transporter PIT-1 expression.

Belmokhtar K, Ortillon J, Jaisson S, Massy ZA, Boulagnon Rombi C, Doué M, Maurice P, Fritz G, Gillery P, Schmidt AM, Rieu P, Touré F.

Nephrol Dial Transplant. 2019 Feb 18. pii: gfz012. doi: 10.1093/ndt/gfz012. [Epub ahead of print]

PMID:
30778553
32.

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):208-230. doi: 10.1093/ndt/gfy407.

PMID:
30753708
33.

Obesity phenotype and patient-reported outcomes in moderate and severe chronic kidney disease: a cross-sectional study from the CKD-REIN cohort study.

Schweitzer ML, Stengel B, Legrand K, Briançon S, Jacquelinet C, Combe C, Fouque D, Massy ZA, Laville M, Frimat L, Ayav C.

Qual Life Res. 2019 Jul;28(7):1873-1883. doi: 10.1007/s11136-019-02110-2. Epub 2019 Jan 18.

PMID:
30659448
34.

Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury.

Veldeman L, Vanmassenhove J, Van Biesen W, Massy ZA, Liabeuf S, Glorieux G, Vanholder R.

Int Urol Nephrol. 2019 Feb;51(2):293-302. doi: 10.1007/s11255-018-2056-x. Epub 2019 Jan 2.

PMID:
30604232
35.

Author Correction: Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0099-y.

PMID:
30538326
36.

Lancet Countdown paper: what does it mean for nephrology?

Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Massy Z, Rychlík I, Soler MJ, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Jan 1;34(1):4-6. doi: 10.1093/ndt/gfy369. No abstract available.

PMID:
30496519
37.

International comparison of trends in patients commencing renal replacement therapy by primary renal disease.

Stel VS, Awadhpersad R, Pippias M, Ferrer-Alamar M, Finne P, Fraser SD, Heaf JG, Hemmelder MH, Martínez-Castelao A, de Meester J, Palsson R, Prischl FC, Segelmark M, Traynor JP, Santamaria R, Reisaeter AV, Massy ZA, Jager KJ.

Nephrology (Carlton). 2019 Oct;24(10):1064-1076. doi: 10.1111/nep.13531. Epub 2019 Apr 29.

PMID:
30456883
38.

Hyponatremia and MAP-kinase inhibitors in malignant melanoma: Frequency, pathophysiological aspects and clinical consequences.

Assan F, Vilaine E, Wagner S, Longvert C, Saiag P, Seidowsky A, Bourgault-Villada I, Massy ZA.

Pigment Cell Melanoma Res. 2019 Mar;32(2):326-331. doi: 10.1111/pcmr.12749. Epub 2018 Nov 22. Review.

PMID:
30387922
39.

Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2018 Dec;14(12):727-749. doi: 10.1038/s41581-018-0072-9. Review. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

PMID:
30361677
40.

Chronic kidney failure mineral bone disorder leads to a permanent loss of hematopoietic stem cells through dysfunction of the stem cell niche.

Aleksinskaya MA, Monge M, Siebelt M, Slot EM, Koekkoek KM, de Bruin RG, Massy ZA, Weinans H, Rabelink TJ, Fibbe WE, Jan van Zonneveld A, van Pel M.

Sci Rep. 2018 Oct 18;8(1):15385. doi: 10.1038/s41598-018-33979-7.

41.

Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions.

Maciel RAP, Cunha RS, Busato V, Franco CRC, Gregório PC, Dolenga CJR, Nakao LS, Massy ZA, Boullier A, Pecoits-Filho R, Stinghen AEM.

Toxins (Basel). 2018 Oct 7;10(10). pii: E404. doi: 10.3390/toxins10100404.

42.

From old uraemic toxins to new uraemic toxins: place of 'omics'.

Massy ZA, Liabeuf S.

Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii2-iii5. doi: 10.1093/ndt/gfy212.

43.

Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients ages 20-50 years: a study by the ERA-EDTA Registry.

Pippias M, Jager KJ, Åsberg A, Berger SP, Finne P, Heaf JG, Kerschbaum J, Lempinen M, Magaz Á, Massy ZA, Stel VS.

Nephrol Dial Transplant. 2018 Sep 7. doi: 10.1093/ndt/gfy268. [Epub ahead of print]

PMID:
30203080
44.

Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease.

Villain C, Metzger M, Combe C, Fouque D, Frimat L, Jacquelinet C, Laville M, Briançon S, Klein J, Schanstra JP, Robinson BM, Mansencal N, Stengel B, Massy ZA; Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Investigators .

Nephrol Dial Transplant. 2018 Aug 28. doi: 10.1093/ndt/gfy277. [Epub ahead of print]

PMID:
30169874
45.

Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.

Hruskova Z, Pippias M, Stel VS, Abad-Díez JM, Benítez Sánchez M, Caskey FJ, Collart F, De Meester J, Finne P, Heaf JG, Magaz A, Palsson R, Reisæter AV, Salama AD, Segelmark M, Traynor JP, Massy ZA, Jager KJ, Tesar V.

Am J Kidney Dis. 2019 Feb;73(2):184-193. doi: 10.1053/j.ajkd.2018.05.016. Epub 2018 Aug 16.

PMID:
30122544
46.

Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort.

Laville SM, Metzger M, Stengel B, Jacquelinet C, Combe C, Fouque D, Laville M, Frimat L, Ayav C, Speyer E, Robinson BM, Massy ZA, Liabeuf S; Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Collaborators.

Br J Clin Pharmacol. 2018 Dec;84(12):2811-2823. doi: 10.1111/bcp.13738. Epub 2018 Sep 24.

PMID:
30110711
47.

The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council.

Zoccali C, Arici M, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Malyszko J, Massy Z, Rychlík I, Spasovski G.

Clin Kidney J. 2018 Aug;11(4):437-442. doi: 10.1093/ckj/sfy064. Epub 2018 Jul 31.

48.

Mortality due to bleeding, myocardial infarction and stroke in dialysis patients.

Ocak G, Noordzij M, Rookmaaker MB, Cases A, Couchoud C, Heaf JG, Jarraya F, De Meester J, Groothoff JW, Waldum-Grevbo BE, Palsson R, Resic H, Remón C, Finne P, Stendahl M, Verhaar MC, Massy ZA, Dekker FW, Jager KJ.

J Thromb Haemost. 2018 Oct;16(10):1953-1963. doi: 10.1111/jth.14254. Epub 2018 Aug 22.

PMID:
30063819
49.

Cognitive Impairments and Dysexecutive Behavioral Disorders in Chronic Kidney Disease.

Puy L, Bugnicourt JM, Liabeuf S, Desjardins L, Roussel M, Diouf M, Chillon JM, Choukroun G, Massy ZA, Godefroy O.

J Neuropsychiatry Clin Neurosci. 2018 Fall;30(4):310-317. doi: 10.1176/appi.neuropsych.18030047. Epub 2018 Jul 26.

PMID:
30045680
50.

The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders.

Assem M, Lando M, Grissi M, Kamel S, Massy ZA, Chillon JM, Hénaut L.

Toxins (Basel). 2018 Jul 22;10(7). pii: E303. doi: 10.3390/toxins10070303. Review.

Supplemental Content

Support Center